Medicare Costs for Neovascular Age-Related Macular Degeneration, 1994-2007

The introduction of anti-VEGF intravitreal injections has offered remarkable clinical benefits for patients with neovascular AMD, but these benefits have come at the cost of an increased financial burden of providing care for these patients.